SCHEMBL30748992

SCHEMBL30748992

O=C1CCc2cnc(CO)nc2N1c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.43
HPGD P15428 1/20 0.43
ALDH1A1 P00352 4/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GFER P55789 1/20 0.40
MGLL Q99685 1/20 0.40
LMNA P02545 2/20 0.39
POLB P06746 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PLCG1 P19174 1/20 0.38
MMP2 P08253 2/20 0.37
MMP3 P08254 2/20 0.37
MMP9 P14780 2/20 0.37
MMP13 P45452 2/20 0.37
USP2 O75604 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749142 0.83 ALDH1A1 (0.45) KMT2AHPGDALDH1A1NPSR1GFER
SCHEMBL30748892 0.81 MGLL (0.41) KMT2AHPGDALDH1A1NPSR1GFER
SCHEMBL30748788 0.80 MGLL (0.40) KMT2AHPGDALDH1A1NPSR1GFER
SCHEMBL30749006 0.76 EGLN1 (0.44) HPGDALDH1A1NPSR1MGLLPOLB
SCHEMBL17281692 0.73 MGLL (0.65) KMT2AHPGDALDH1A1NPSR1GFER
SCHEMBL30748879 0.72 ALDH1A1 (0.44) KMT2AHPGDALDH1A1NPSR1GFER
SCHEMBL30748853 0.70 POLB (0.36) POLBL3MBTL1PLCG1SMN1; SMN2
SCHEMBL30749080 0.69 PSEN1 (0.39) POLBL3MBTL1
SCHEMBL30748920 0.67 LTA4H (0.40) POLBL3MBTL1
SCHEMBL32668241 0.67 POLB (0.70) KMT2AHPGDALDH1A1MGLLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT KMT2A 1604/4885HPGD 426/4885ALDH1A1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.